117 related articles for article (PubMed ID: 38411494)
21. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
22. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
[TBL] [Abstract][Full Text] [Related]
23. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
[TBL] [Abstract][Full Text] [Related]
25. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma.
Ji B; Cai H; Yang Y; Peng F; Song M; Sun K; Yan F; Liu Y
Acta Biomater; 2020 Jul; 111():363-372. PubMed ID: 32434082
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.
Afifi AM; El-Husseiny AM; Tabashy RH; Khalil MA; El-Houseini ME
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3007-3013. PubMed ID: 31653148
[TBL] [Abstract][Full Text] [Related]
27. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
28. Folic acid-nanoscale gadolinium-porphyrin metal-organic frameworks: fluorescence and magnetic resonance dual-modality imaging and photodynamic therapy in hepatocellular carcinoma.
Chen Y; Liu W; Shang Y; Cao P; Cui J; Li Z; Yin X; Li Y
Int J Nanomedicine; 2019; 14():57-74. PubMed ID: 30587985
[TBL] [Abstract][Full Text] [Related]
29. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
Younis MA; Khalil IA; Elewa YHA; Kon Y; Harashima H
J Control Release; 2021 Mar; 331():335-349. PubMed ID: 33484779
[TBL] [Abstract][Full Text] [Related]
30. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
31. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
32. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy.
Zheng L; Li C; Huang X; Lin X; Lin W; Yang F; Chen T
Biomaterials; 2019 Sep; 216():119220. PubMed ID: 31200144
[TBL] [Abstract][Full Text] [Related]
33. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
34. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
Feng S; Zhou J; Li Z; Appelman HD; Zhao L; Zhu J; Wang TD
Colloids Surf B Biointerfaces; 2019 Dec; 184():110498. PubMed ID: 31536939
[TBL] [Abstract][Full Text] [Related]
36. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
37. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
[TBL] [Abstract][Full Text] [Related]
38. Sinoporphyrin sodium based sonodynamic therapy induces anti-tumor effects in hepatocellular carcinoma and activates p53/caspase 3 axis.
Li E; Sun Y; Lv G; Li Y; Zhang Z; Hu Z; Cao W
Int J Biochem Cell Biol; 2019 Aug; 113():104-114. PubMed ID: 30660690
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma.
Park W; Cho S; Ji J; Lewandowski RJ; Larson AC; Kim DH
Radiol Imaging Cancer; 2021 Jan; 3(1):e200006. PubMed ID: 33575658
[TBL] [Abstract][Full Text] [Related]
40. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
